Cargando…

Junctional adhesion molecule-A is overexpressed in advanced multiple myeloma and determines response to oncolytic reovirus

Despite the development of several new agents for multiple myeloma (MM) therapy over the last decade, drug resistance continues to be a significant problem. Patients with relapsed/refractory disease have high mortality rates and desperately need new precision approaches that directly target specific...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kelly, Kevin R., Espitia, Claudia M., Zhao, Weiguo, Wendlandt, Erik, Tricot, Guido, Zhan, Fenghuang, Carew, Jennifer S., Nawrocki, Steffan T.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2015
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4747405/ https://www.ncbi.nlm.nih.gov/pubmed/26513296

Ejemplares similares

Oncolytic reovirus sensitizes multiple myeloma cells to anti-PD-L1 therapy
por: Kelly, Kevin R., et al.
Publicado: (2017)

Oncolytic reovirus inhibits angiogenesis through induction of CXCL10/IP-10 and abrogation of HIF activity in soft tissue sarcomas
por: Carew, Jennifer S., et al.
Publicado: (2017)

Targeting JAK/STAT Signaling Antagonizes Resistance to Oncolytic Reovirus Therapy Driven by Prior Infection with HTLV-1 in Models of T-Cell Lymphoma
por: Islam, Shariful, et al.
Publicado: (2021)

Cancer stem cells are the cause of drug resistance in multiple myeloma: fact or fiction?
por: Franqui-Machin, Reinaldo, et al.
Publicado: (2015)

Oncolytic Viruses for Multiple Myeloma Therapy
por: Calton, Christine M., et al.
Publicado: (2018)

Gastrointestinal cancer-associated fibroblasts expressing Junctional Adhesion Molecule-A are amenable to infection by oncolytic reovirus
por: Harryvan, Tom J., et al.
Publicado: (2022)

NEK2 mediates ALDH1A1-dependent drug resistance in multiple myeloma
por: Yang, Ye, et al.
Publicado: (2014)

Genetic Analysis of Multiple Myeloma Identifies Cytogenetic Alterations Implicated in Disease Complexity and Progression
por: Li, Can, et al.
Publicado: (2021)

Structure of Reovirus σ1 in Complex with Its Receptor Junctional Adhesion Molecule-A
por: Kirchner, Eva, et al.
Publicado: (2008)

Reolysin is a novel reovirus-based agent that induces endoplasmic reticular stress-mediated apoptosis in pancreatic cancer
por: Carew, J S, et al.
Publicado: (2013)

Copper–zinc superoxide dismutase-mediated redox regulation of bortezomib resistance in multiple myeloma
por: Salem, Kelley, et al.
Publicado: (2014)

Nek2 Is a Novel Regulator of B Cell Development and Immunological Response
por: Gu, Zhimin, et al.
Publicado: (2014)

Past, Present and Future of Oncolytic Reovirus
por: Müller, Louise, et al.
Publicado: (2020)

NEK2 Promotes Aerobic Glycolysis in Multiple Myeloma Through Regulating Splicing of Pyruvate Kinase
por: Gu, Zhimin, et al.
Publicado: (2017)

ABCG2 Overexpression Contributes to Pevonedistat Resistance
por: Kathawala, Rishil J., et al.
Publicado: (2020)

Oncolytic Reovirus in Canine Mast Cell Tumor
por: Hwang, Chung Chew, et al.
Publicado: (2013)

Oncolytic Reovirus Infection Is Facilitated by the Autophagic Machinery
por: Kemp, Vera, et al.
Publicado: (2017)

Targeting heparanase overcomes chemoresistance and diminishes relapse in myeloma
por: Ramani, Vishnu C., et al.
Publicado: (2015)

Upregulation of FOXM1 leads to diminished drug sensitivity in myeloma
por: Gu, Chunyan, et al.
Publicado: (2018)

Moving beyond hydroxychloroquine: the novel lysosomal autophagy inhibitor ROC-325 shows significant potential in preclinical studies
por: Jones, Trace M., et al.
Publicado: (2019)

Correction to: Upregulation of FOXM1 leads to diminished drug sensitivity in myeloma
por: Gu, Chunyan, et al.
Publicado: (2019)

Isolation of Reovirus T3D Mutants Capable of Infecting Human Tumor Cells Independent of Junction Adhesion Molecule-A
por: van den Wollenberg, Diana J. M., et al.
Publicado: (2012)

The oncolytic effect in vivo of reovirus on tumour cells that have survived reovirus cell killing in vitro
por: Alain, T, et al.
Publicado: (2006)

VTD-melphalan is well tolerated and results in very high rates of stringent CR and MRD-negative status in multiple myeloma
por: Nadiminti, Kalyan, et al.
Publicado: (2017)

Synergistic effects of oncolytic reovirus and docetaxel chemotherapy in prostate cancer
por: Heinemann, Lucy, et al.
Publicado: (2011)

The oncolytic effects of reovirus in canine solid tumor cell lines
por: IGASE, Masaya, et al.
Publicado: (2015)

Exploring Reovirus Plasticity for Improving Its Use as Oncolytic Virus
por: Kemp, Vera, et al.
Publicado: (2015)

Role of Myeloid Cells in Oncolytic Reovirus-Based Cancer Therapy
por: Kumar, Vishnupriyan, et al.
Publicado: (2021)

Multiple Myeloma Tumor Cells are Selectively Killed by Pharmacologically-dosed Ascorbic Acid
por: Xia, Jiliang, et al.
Publicado: (2017)

Alteration of mitochondrial biogenesis promotes disease progression in multiple myeloma
por: Zhan, Xin, et al.
Publicado: (2017)

Targeted CUL4A inhibition synergizes with cisplatin to yield long-term survival in models of head and neck squamous cell carcinoma through a DDB2-mediated mechanism
por: Jones, Trace M., et al.
Publicado: (2022)

Geographic and Racial Disparities in Access to Chimeric Antigen Receptor–T Cells and Bispecific Antibodies Trials for Multiple Myeloma
por: Alqazaqi, Raghad, et al.
Publicado: (2022)

Inhibition of Nek2 by Small Molecules Affects Proteasome Activity
por: Meng, Lingyao, et al.
Publicado: (2014)

Cytokine-induced killer cell delivery enhances the antitumor activity of oncolytic reovirus
por: Zhao, Xing, et al.
Publicado: (2017)

Anti-tumor efficacy of oncolytic reovirus against gastrointestinal stromal tumor cells
por: Inagaki, Yusuke, et al.
Publicado: (2017)

Doxorubicin Conjugation to Reovirus Improves Oncolytic Efficacy in Triple-Negative Breast Cancer
por: Berry, Jameson T.L., et al.
Publicado: (2020)

NAD+ depletion enhances reovirus-induced oncolysis in multiple myeloma
por: Kennedy, Barry E., et al.
Publicado: (2022)

Upregulation of FOXM1 in a subset of relapsed myeloma results in poor outcome
por: Gu, Chunyan, et al.
Publicado: (2018)

Heightened JNK Activation and Reduced XIAP Levels Promote TRAIL and Sunitinib-Mediated Apoptosis in Colon Cancer Models
por: Mahalingam, Devalingam, et al.
Publicado: (2019)

Targeting NEDDylation is a Novel Strategy to Attenuate Cisplatin-induced Nephrotoxicity
por: Jones, Trace M., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_cf6ou5pkuqel7mplgt4p5c8c46